Mirum Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Mirum Pharmaceuticals has a total shareholder equity of $248.7M and total debt of $306.4M, which brings its debt-to-equity ratio to 123.2%. Its total assets and total liabilities are $646.6M and $398.0M respectively.
Key information
123.2%
Debt to equity ratio
US$306.42m
Debt
Interest coverage ratio | n/a |
Cash | US$286.33m |
Equity | US$248.67m |
Total liabilities | US$397.95m |
Total assets | US$646.62m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 08D's short term assets ($387.5M) exceed its short term liabilities ($87.1M).
Long Term Liabilities: 08D's short term assets ($387.5M) exceed its long term liabilities ($310.9M).
Debt to Equity History and Analysis
Debt Level: 08D's net debt to equity ratio (8.1%) is considered satisfactory.
Reducing Debt: 08D's debt to equity ratio has increased from 0% to 123.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 08D has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 08D has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.